ES2914781T3 - Composiciones para el tratamiento de la amiloidosis - Google Patents

Composiciones para el tratamiento de la amiloidosis Download PDF

Info

Publication number
ES2914781T3
ES2914781T3 ES17740200T ES17740200T ES2914781T3 ES 2914781 T3 ES2914781 T3 ES 2914781T3 ES 17740200 T ES17740200 T ES 17740200T ES 17740200 T ES17740200 T ES 17740200T ES 2914781 T3 ES2914781 T3 ES 2914781T3
Authority
ES
Spain
Prior art keywords
antibody
patient
peripheral neuropathy
treatment
amyloidosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17740200T
Other languages
English (en)
Spanish (es)
Inventor
Gene G Kinney
Spencer D Guthrie
Martin Koller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prothena Biosciences Ltd
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Application granted granted Critical
Publication of ES2914781T3 publication Critical patent/ES2914781T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES17740200T 2016-06-30 2017-06-30 Composiciones para el tratamiento de la amiloidosis Active ES2914781T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662357151P 2016-06-30 2016-06-30
PCT/US2017/040289 WO2018005967A1 (en) 2016-06-30 2017-06-30 Compositions for treating amyloidosis

Publications (1)

Publication Number Publication Date
ES2914781T3 true ES2914781T3 (es) 2022-06-16

Family

ID=59351103

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17740200T Active ES2914781T3 (es) 2016-06-30 2017-06-30 Composiciones para el tratamiento de la amiloidosis

Country Status (16)

Country Link
US (2) US20190169280A1 (enExample)
EP (1) EP3478713B1 (enExample)
JP (3) JP2019519584A (enExample)
CY (1) CY1125536T1 (enExample)
DK (1) DK3478713T3 (enExample)
ES (1) ES2914781T3 (enExample)
HR (1) HRP20220979T8 (enExample)
HU (1) HUE059400T2 (enExample)
LT (1) LT3478713T (enExample)
MA (1) MA45552A (enExample)
PL (1) PL3478713T3 (enExample)
PT (1) PT3478713T (enExample)
RS (1) RS63446B1 (enExample)
SI (1) SI3478713T1 (enExample)
SM (1) SMT202200261T1 (enExample)
WO (1) WO2018005967A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210017278A1 (en) * 2018-03-23 2021-01-21 Prothena Biosciences Limited Treatment and Prophylaxis of Amyloidosis
CA3129890A1 (en) * 2019-02-12 2020-08-20 Prothena Biosciences Limited Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells
MA55209A (fr) 2019-03-05 2022-01-12 Prothena Biosciences Ltd Procédés de traitement de l'amylose al
EP4022062A1 (en) * 2019-08-30 2022-07-06 Alnylam Pharmaceuticals, Inc. Neurofilament light chain (nfl) as a biomarker for transthyretin amyloidosis polyneuropathy
EP4168451A2 (en) * 2020-06-22 2023-04-26 NGM Biopharmaceuticals, Inc. Lair-1-binding agents and methods of use thereof
TW202332465A (zh) * 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
WO2009086539A2 (en) 2007-12-28 2009-07-09 Elan Pharmaceuticals, Inc. Treatment and prophylaxis of amyloidosis
BR112014009866A2 (pt) 2011-10-25 2018-09-04 Onclave Therapeutics Limited formulações de anticorpos e métodos

Also Published As

Publication number Publication date
JP2019519584A (ja) 2019-07-11
SI3478713T1 (sl) 2022-06-30
EP3478713B1 (en) 2022-05-11
PT3478713T (pt) 2022-05-27
HRP20220979T1 (hr) 2022-11-11
MA45552A (fr) 2019-05-08
US20210079078A1 (en) 2021-03-18
JP2024127990A (ja) 2024-09-20
RS63446B1 (sr) 2022-08-31
CY1125536T1 (el) 2025-05-09
HUE059400T2 (hu) 2022-11-28
DK3478713T3 (da) 2022-06-20
US20190169280A1 (en) 2019-06-06
EP3478713A1 (en) 2019-05-08
WO2018005967A1 (en) 2018-01-04
PL3478713T3 (pl) 2022-10-10
JP2022121658A (ja) 2022-08-19
LT3478713T (lt) 2022-06-10
HRP20220979T8 (hr) 2023-02-03
SMT202200261T1 (it) 2022-07-21

Similar Documents

Publication Publication Date Title
US10517830B2 (en) Antibody formulations and methods
JP2024127990A (ja) アミロイドーシスを処置するための組成物
BR112019015426A2 (pt) Composição farmacêutica para uso no tratamento ou prevenção de uma doença relacionada a c5 e um método para tratar ou prevenir uma doença rela-cionada a c5
ES2688726T5 (es) Métodos y formulaciones que permiten la modulación de respuestas inmunitarias relacionadas con la administración de un fármaco biofarmacéutico
JP6255099B2 (ja) Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
JP7619953B2 (ja) Ａｌアミロイドーシスを処置する方法
TW202003046A (zh) 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
JP2014500278A (ja) 二重特異性ｓｃＦｖコンジュゲートの投薬量および投与
Ashfaque et al. Suppression to removal, an emerging therapeutic approach for AL amyloidosis: A comprehensive review with early human data and pharmacokinetics of CAEL-101 antibody
TW202346335A (zh) 治療al類澱粉變性症之方法
WO2023174408A1 (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
TW202332465A (zh) 治療al類澱粉變性症之方法
HK40008815B (en) Compositions for treating amyloidosis
US20250002569A1 (en) Method of treating osteoarthritis
US20250312339A1 (en) Methods and compositions comprising a shp2 inhibitor and a pd-li binding antagonist
WO2026022216A1 (en) Uses of anti-cd127 antibodies in the treatment of inflammatory bowel diseases
WO2025170969A1 (en) Methods of treating al amyloidosis
BR112020019172A2 (pt) tratamento e profilaxia de amiloidose
KR20170138405A (ko) 다발성 골수종의 로네파르스탯트 병행 치료